Method of identifying triple negative breast cancer
AssigneeWashington University
InventorsSusana Gonzalo, Ignacio Gonzalez-Suarez, David Grotsky
Life of this patent
Estimating the term…
Abstract
The present invention provides means for identifying or classifying breast tumors based on the levels of nuclear cathepsin-L (CTSL) and nuclear p53 binding protein (53BP1), and methods of treating thereof.
Claims19
A method for classifying a breast tumor, the method comprising:
- (a) obtaining a sample of a breast tumor;
- (b) processing the sample in vitro to determine the levels of nuclear cathepsin L and nuclear 53BP1 in at least one tumor cell comprising the sample;
- and
- (c) classifying the tumor as having (i) high nuclear cathepsin L and low nuclear 53BP1, (ii) high nuclear cathepsin L and high nuclear 53BP1, or (ii) low nuclear cathepsin L and low nuclear 53BP1.
A method for increasing the sensitivity of a tumor cell to a DNA-damaging agent, the method comprising contacting the tumor cell with an effective amount of a cathepsin L inhibitor and a DNA-damaging agent.
A method for predicting the effectiveness of a DNA damaging agent in reducing tumor growth in a subject in need thereof, the method comprising:
- (a) obtaining a sample of a breast tumor from the subject;
- (b) processing the sample in vitro to determine the levels of nuclear CTSL and nuclear 53BP1 in at least one tumor cell comprising the sample;
- (c) classifying the tumor as non-responsive to a DNA-damaging agents if the sample has (i) high nuclear CTSL and low nuclear 53BP1 or (ii) low nuclear CTSL and low nuclear 53BP1;
- and
- (d) identifying a subject with a tumor classified as non-responsive to a DNA-damaging agent as a subject for which a DNA-damaging agent would not be effective.
Dependencies are inferred from the claim text.